Health-Related Quality of Life in Adult Patients With Focal Segmental Glomerulosclerosis (FSGS): Sparsentan Versus Irbesartan
Congress materials
Explore our congress materials
Encore posters are re-presentations of previously published data.
Filter by:
Year
Year
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Resource type
Resource type
×Filter by:
Year
Year
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Resource type
Resource type
×Results156
Sort by
Urinary Biomarker Analysis Reveals Rapid Intrarenal Anti‑inflammatory and Anti-fibrotic Effects of Sparsentan in IgA Nephropathy in the SPARTAN Study
Congress Name – 2025
Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial
2025
Effects of Sparsentan after Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients with IgA Nephropathy (IgAN) in the PROTECT Trial
2025
Patients With Focal Segmental Glomerulosclerosis (FSGS) Achieved Low Proteinuria Targets Earlier and More Often With Sparsentan (SPAR) vs Irbesartan (IRB) in DUPLEX
2025
Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial
2025
Join the
Conversation
Sign up to receive updates on the latest news, resources, and data on rare disease research.
Subscribe now
Connect with our MSL team today
Arrange a meeting with a member of our medical science liaison (MSL) team to discuss the latest insights, clinical trial data, and management trends.
Find your MSL